Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
Status:
Completed
Trial end date:
2010-10-21
Target enrollment:
Participant gender:
Summary
This study will investigate clinical activity, safety, and tolerability of the
anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of
glioblastoma multiforme (GBM).